Heart Failure and CBD
February 21st, 2019
Exclusive, News, Top Story
Heart failure (HF) affects more than 6 million adults in Canada and the United States and is a leading cause of hospitalization, with costs exceeding $30 billion each year in the US alone. People with HF suffer from shortness of breath, rapid heart rate, edema, reduced exercise capacity, often struggle with simple daily activities, and are frequently hospitalized. For many, these symptoms significantly reduce quality of life.
There are two main types of HF: heart failure with poor contraction or reduced ejection fraction (HFrEF), also known as systolic heart failure, and heart failure with poor relaxation or preserved ejection fraction (HFpEF), also known as diastolic heart failure. About half of HF patients suffer from HFpEF. Unfortunately, treatment for HFpEF has not advanced over the last couple of decades, with the standard of care currently involving the use of diuretics such as Lasix to relieve swelling of the tissue by removing water and salt. Diuretics do improve symptoms but there is a lack of data indicating that diuretics are actually effective in the treatment of the causes of HF.
There is, however, considerable research indicating that cannabidiol, or CBD, has potent anti-inflammatory and anti-fibrotic properties that could prove beneficial for treating HFpEF. Derived from the hemp or cannabis plant, CBD is getting a lot of attention as researchers are finally able to legally study the molecule. One issue with CBD lies with its delivery, due to CBD’s hydrophobic nature. If taken orally, the liver removes much of the CBD before it enters the bloodstream, with the result that most current treatments involve very high and imprecise dosing.
Cardiol Therapeutics (TSX: CRDL) (OTC: CRTPF) is a biotech company with a strong background in heart therapy research, a proven and patented nanotechnology solution for the targeted delivery of CBD and other lipophilic drugs to inflamed tissues, and a supplier of ultra-pure pharmaceutical CBD to further its research into the treatment of HFpEF. Cardiol is also advancing an immunotherapeutic for the treatment of glioblastoma multiforme (GBM), the deadly brain cancer that took the lives of Senators Ted Kennedy and John McCain. The company believes a combination of cannabinoids and cell-based immunotherapies shows great promise in the treatment of GBM. Cardiol will soon be launching its ultra-pure pharmaceutical CBD oil into the Canadian medical market, a move the company hopes will generate significant revenue in the short term.
Nanotechnology Enables Targeted CBD Delivery
Cardiol has developed a unique patented system whereby lipophilic (fat soluble) drugs like CBD, are encased in a hydrophilic (water soluble) shell. This shell allows the active lipophilic ingredient to effectively circulate in the bloodstream. Normally, taking CBD orally results in less than 10% bioavailability, due to “first-pass” metabolism by the liver. Cardiol’s nanotherapeutics delivery methodology, which avoids the oral route, allows for much higher levels of lipophilic active ingredients in the bloodstream and, most importantly, has the potential to deliver drugs to specific sites of inflammation in the body. This proprietary technology could be licensed or partnered with other companies. Furthermore, the opportunity here is not just limited to CBD delivery, as these same problems have vexed companies developing other lipophilic drugs.
Illustration of Cardiol’s patented nanotechnology
By utilizing this nanotechnology delivery system, Cardiol has found in an experimental model that its nanoparticles preferentially accumulate in inflamed heart tissue. These findings validate the platform’s targeted delivery and point the way to further research through a clinical trial program.
Cardiol is collaborating with researchers and opinion leaders at international centers of excellence to leverage multidisciplinary expertise in drug delivery, drug formulation, nanotherapeutics, cardiac physiology, and heart failure to advance its clinical programs. The company’s nanotechnology is developed in conjunction with the National Institute for Nanotechnology, a joint venture of the University of Alberta, the National Research Council of Canada, and the Government of Alberta.
The company is also collaborating with the DeBakey Heart & Vascular Center in Houston, one of the leading heart hospitals in the United States, to investigate its nanotechnology as it relates directly to treatment of heart failure.
The company has partnered with TecSalud del Tecnológico de Monterrey (“TecSalud”) in Mexico in a US$3 million R&D program. TecSalud has collaborative relationships with the DeBakey Heart & Vascular Center and the Massachusetts Institute of Technology for its nanotechnology programs.
Overall, Cardiol is collaborating with some of the world’s best heart and nanotech research organizations to develop its diverse product pipeline.
Cardiol’s President and CEO, David Elsley, previously founded Vasogen Inc. in the 1990’s. Vasogen was a biotech focused on treating heart conditions and inflammatory disease, and under Mr. Elsley’s watch it went public on the NASDAQ and the TSX, reaching a market capitalization north of US$1 billion. His experience in founding and growing a company from start-up through clinical trials is essential as he guides Cardiol Therapeutics through a similar growth process.
He is joined by many other proven industry leaders, including the company’s Chief Medical Officer, Dr. Eldon Smith. Dr. Smith is the former Head of Cardiology and Dean of Medicine at the University of Calgary. He also spent 14 years as Editor-in-Chief of the Canadian Journal of Cardiology. Dr. Smith has served on a wide variety of medical societies and associations, both in the private and public sector. He also brings a wealth of public company experience to Cardiol, having served as Director of more than ten public companies.
Collectively, Cardiol’s executive team has extensive scientific, regulatory, and public company experience. This leadership is essential to the company’s development and potential for success, as it navigates the complexities of bringing HF drug candidates through the clinical trial process to potential commercialization.
2019 a Pivotal Year for Cardiol
After going public with an IPO on the Toronto Stock Exchange on December 20, 2018, Cardiol Therapeutics is looking forward to an eventful 2019. The company is introducing ultra-pure pharmaceutical CBD to a Canadian medical market that is currently experiencing a major supply shortfall following the full legalization of cannabis. Cardiol views this as a significant revenue opportunity, and it serves as a major differentiator when compared to other biotech companies exclusively involved in clinical research. In lockstep, Cardiol expects to advance its product pipeline, specifically, its CBD-based HF treatment.
There is great upside potential for Cardiol as the company advances its therapies for the treatment of HF. Concurrently, the company is advancing its immunotherapeutic for the treatment of GBM, the most frequent and deadliest form of cancer affecting the brain. Treatments in the US for GBM are eligible for orphan drug status, meaning clinical research is subject to Fast Track review, with the intent of getting successful treatments to market as quickly as possible.
There are several potential milestones and catalysts for CRDL over the coming months. Combining the proven value creation of biotech drug development with the explosive potential of cannabinoid-based therapies, while targeting an enormous heart failure market, Cardiol Therapeutics is well positioned for significant growth.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.